Liraglutide (Victoza®)

Assessment Status Assessment process complete
Drug Liraglutide
Brand Victoza®
Indication For treatment of adults with type 2 diabetes mellitus.
Assessment Process
Rapid review commissioned 01/09/2009
Rapid review completed 07/10/2009
Rapid review outcome Full Pharmacoeconomic Assessment Not Recommended
Full pharmacoeconomic assessment commissioned by HSE 26/10/2016
Pre-submission consultation with Applicant 21/02/2017
Full submission received from Applicant 29/08/2017
Preliminary review sent to Applicant 17/08/2018
NCPE assessment re-commenced 30/10/2018
Factual accuracy sent to Applicant 07/02/2019
NCPE assessment re-commenced 18/02/2019
NCPE assessment completed 07/03/2019
NCPE assessment outcome The NCPE recommends that liraglutide (Victoza®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*. 

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013

Technical Summary